Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.79
+0.01 (0.05%)
Jul 30, 2026, 10:40 AM EDT - Market open
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $36.22M in the quarter ending March 31, 2026, with 77.54% growth. This brings the company's revenue in the last twelve months to $122.29M, up 201.29% year-over-year. In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth.
Revenue (ttm)
$122.29M
Revenue Growth
+201.29%
P/S Ratio
4.73
Revenue / Employee
$2,004,738
Employees
61
Market Cap
578.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 98.99M |
| 4D Molecular Therapeutics | 88.24M |
| Verastem | 49.59M |
| Prime Medicine | 4.03M |
| Shattuck Labs | 1.00M |
| Silence Therapeutics | 839.00K |
| Altimmune | 36.00K |
ZVRA News
- 2 days ago - ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
- 3 days ago - Spruce Biosciences appoints Quartel as Chief Medical Officer - TheFly
- 3 days ago - Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim - TheFly
- 3 days ago - Zevra Therapeutics price target lowered to $24 from $27 at BTIG - TheFly
- 3 days ago - Zevra Therapeutics price target lowered to $20 from $29 at Canaccord - TheFly
- 5 days ago - EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright - TheFly
- 6 days ago - Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol - TheFly
- 6 days ago - Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA - TheFly